Rationale of Combination
It has been demonstrated by recent studies. Concomitant administration of Cefpodoxime
shows better symptoms relief compared with the modest improvement of upper respiratory tract infections like Rhintis
and Lower respiratory tract infections and help to cure Pneumonia
, Acute bronchitis
Therapeutic Evidence Favouring this Medication Therapy
- Clinically improved immunological parameters.
- Wide range of bacterial infections covered due to wide antibacterial spectrum.
- Short course therapy with effective cure.
- Resistance patterns of respiratory pathogens favours this medication therapy.
USPs of the Combination of Cefpodoxime + Ofloxacin
- Wider spectrum of activity against RTI pathogens.
- Prevents attainment of antimi crobialresistance by eliminating montherapy .
- Better success rate.
- Less chances of relapse.
Double attack of organisms since the mode of action is different, hence assuring complete cure.
Allows for Synergistic effect of the drugs.
Better patient compliance – the patients has to take only one tablets as against 2 separately.
Pathogens Responsible For RTI
Most Common Bacterial Pathogens in AOM, ABRS, AECBs, and CAP.
|| AQM (%) ||ABRS (%) ||AECBs (%)||CAP (%)
Typhoid fever bacterial (Salmonella Typhi
) is the organism responsible for typhoid fever.
Resistance Patterns of Respiratory Pathogens Favors this Medication Therapy
||Intermediate Penicillin Resistance
a Penicillin resistance was defined as: intermediate
(MIC 0. 12-1.0mg/L)
and high–level (MIC > 1.0mg/L)
. Macrolide resistance
was defined as erythromycin MIC ≥ mg/
Resistance Patterns of Respiratory Pathogens Favors This Medication Therapy Resistance in H.influenzae
Alexander Project data from 1992 – 1997 indicate that the prevalence of β - lactamase production appears to have reached a steady state in some countries, such as France and the USA, but may be as high as 35% in some areas. Although use of a vaccine against H. Influenzae serotype b (the most virulent serotype) may decrease the importance of this strain, resistant, non – type able strains remain clinically significant community – acquired respiratory tract pathogens.
Resistance in M.catarrhalis
Most (50-80%) isolates of M.catarrhalis isolated during the Alexander Project in 1992 produced β - lactamase. However, this had increased further, to 90-100%, in the participating centres by 1997. Resistance to other (non β-lactam) antibiotic classes was stable in M. catarrhalis (as it was in H. Influenzae).